جستجوی مقالات مرتبط با کلیدواژه "درمان سه دارویی" در نشریات گروه "پزشکی"

Furazolidone has been introduced as an effective drug against helicobacter pylori infection in Iran, but intolerable side-effects may limit its use. We compared quadruple and triple furazolidone-based regimens to achieve an economically affordable regimen with acceptable efficacy rate and fewer complications.Matherials & Patients with H.pylori positive peptic ulcer disease were randomly divided into two groups. They were treated with amoxicillin 1gm/BID, furazolidone 200 mg/BID, omeprazole 20mg/BID with and without bismuth sub-citrate 240 mg/BID for two weeks (AFOB & AFO regimens, respectively) H.pylori eradication was confirmed by 13C-urea breath test 12 weeks after the end of the treatment. Eighty six patients were enrolled but 16 ones discontinued their therapy or follow-up. The eradication rates in AFOB & AFO were 85.3% and 61.1% by per-protocol analysis, respectively (P=0.02), and 67.4% & 51.2% by intention–to-treat analysis respectively (P<0.05). The most frequent adverse effects in the two study groups were weakness, nausea, anorexia and dizziness that demonstrated no significant differences.Discussion & In this study, furazolidone-based triple therapy (without bismuth) was not recommended for H.pylori eradication, due to the lower eradication rate and unchanged frequency of adverse effects.

Helicobacter pylori treatment is advised in all cases of chronic dyspepsia recently but despite several new drugs, treatment failure is probable yet and the choice method to eradicate Hpylori is contraversial. We studied all patients with chronic dyspepsia who referred to endoscopic ward of Imam Reza hospital. After demonstration of Helicobacter pylori infection by rapid urea’s test (RUT), these cases were divided into two groups randomly. The first group was treated by Metronidazole, Amoxicillin and Omeprazole and the second group was treated by previous drugs plus Bismuth Substrate for 2 weeks. Then drug side effects were asked during the first and second week and Helicobacter pylori eradication was evaluated by UBT (Urea Breath test) six weeks after the treatment. Among 56 cases in this study 39.3% were male and 60.7% were female and 41-50 years cases were more frequent. 27 cases (48.2%) were treated by triple therapy and 29 patients (51.8%) were treated by quadruple therapy. Most common symptoms during the first week were abdominal pain and flatulence but during the second week the common side effect was flatulence. Although, treatment side effects were rare in the second week and only 25% of patients had significant symptom. Finally the total treatment success rate was 49% and Helicobacter pylori was eradicated according to UBT in 50% by triple therapy and 48% by quadruple therapy. The difference between two methods was not significant, although treatment success ratio was higher in young people. Triple therapy (Omeprazole, Amoxicillin and Metronidazole) is an effective regimen for the first line therapy in eradication of Helicobacter pylori especially in young people.